Wide Open Agriculture is closing its German plant and pivoting to contract manufacturing in Asia to cut costs and scale lupin ingredient production efficiently under new CEO Craig Swan.
- Immediate wind down of German production facility
- Transition to contract manufacturing targeting 500–1,000 tonnes per annum
- Focus on whole-seed lupin product commercialisation including protein, oil, and fibre
- New CEO Craig Swan to lead strategic execution
- Pre-Feasibility Study underway for future large-scale Australian production
German Facility Closure to Slash Overheads
Wide Open Agriculture Ltd (ASX:WOA) is taking a decisive step to improve its cost structure by immediately winding down its German production facility. Originally acquired through the Prolupin deal, the German plant served as a commercial-scale proof of concept, enabling WOA to validate its proprietary lupin protein isolate technology, secure key regulatory approvals including access to the China market, and build initial customer relationships.
However, the facility’s limited capacity and high operating costs, exacerbated by elevated energy prices in the EU, have made continued owner-operated production uneconomical. WOA’s board has concluded that scaling beyond the German plant’s capabilities would require significant capital investment, which conflicts with the company’s goal of capital-efficient growth. The German site will be idled immediately, with the wind down expected to be complete by mid-2027, and no material ongoing costs anticipated beyond December 2026.
Pivot to Contract Manufacturing in Asia
Replacing the German facility, WOA plans to shift to a contract manufacturing model targeting an initial production scale of 500 to 1,000 tonnes per annum. Asia is the preferred production location due to proximity to key growth markets and a more favourable cost base. This model promises improved unit economics through higher throughput, lower energy and labour costs, and reduced fixed overheads and capital intensity.
WOA is actively engaging with multiple potential manufacturing partners in Asia, aiming to formalise agreements that also safeguard its intellectual property. The contract manufacturing approach allows the company to focus on developing its full-value lupin seed extraction process, commercialising protein, oil, and fibre products without the constraints of owning and operating manufacturing facilities.
Expanding Revenue Streams with Whole-Seed Utilisation
WOA’s strategy extends beyond protein isolate to commercialising co-products derived from the whole lupin seed, notably lupin oil and fibre. Early sales of lupin oil, prized for its oleic acid content and applications in cosmetics and specialty foods, have been secured. The company is also advancing the development of lupin fibre, which independent testing confirms has strong techno-functional properties suitable for diverse food applications.
This multi-product approach is expected to enhance margins per tonne of seed processed, diversify WOA’s customer base across food, beverage, and cosmetics sectors, and strengthen sustainability credentials. The company believes these factors will attract strategic partners and investors, laying a foundation for future profitability.
Long-Term Vision for Large-Scale Australian Production
While the immediate focus is on contract manufacturing and commercial growth, WOA is simultaneously exploring a large-scale Australian production facility capable of processing 10,000+ tonnes per annum. A Pre-Feasibility Study is underway to assess the technical and economic viability of this industrial-scale plant. Any progression beyond this stage would require further feasibility work, funding, and board approval.
WOA’s Chair Justin Brown emphasised the company’s strong foundations, including proven technology, regulatory clearances, and a global distribution network. He highlighted the importance of translating these into long-term shareholder value under the leadership of new CEO Craig Swan, who brings extensive experience in B2B food ingredients and Asian markets.
Outlook Hinges on Contract Manufacturing Transition
The critical near-term milestone for WOA is securing a contract manufacturing partner to enable cost-effective scale-up and improved supply capabilities. This transition is expected to materially enhance unit economics by removing the fixed-cost burden of the German facility and leveraging lower-cost production locations. The company plans to update the market as partner arrangements progress.
With a leaner cost base, WOA aims to grow revenue across its lupin protein, oil, and fibre portfolio, convert its existing pipeline into contracted supply agreements, and demonstrate the commercial potential of whole-seed processing at scale. The company continues to advance R&D and commercial engagement for its lupin fibre and oil products, seeking to broaden its market footprint.
Bottom Line?
WOA’s shift to contract manufacturing and whole-seed product diversification sets the stage for capital-efficient growth, but execution risk remains around partner selection and scaling timelines.
Questions in the middle?
- Which contract manufacturing partners will WOA ultimately select and on what terms?
- How quickly can WOA ramp production to meet latent demand beyond the German facility’s capacity?
- What progress will the Pre-Feasibility Study for the large-scale Australian plant reveal about future expansion viability?